TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial
Shares of TransCode Therapeutics Inc jumped nearly 19% Thursday following a U.S. regulatory update related to its lead drug program. The stock traded around $10.23, swinging between $9.08 and $12.30, as volume surged to about 11.5 million shares compared to roughly 8,500 the previous day.